Vascular complications in diabetes mellitus are known to be associated with the activation of the protein kinase C (PKC) pathway through the de novo synthesis of diacylglycerol (DAG) from glycolytic intermediates. Specific PKC isoforms, mainly the ␤and ␦-isoforms, have been shown to be persistently activated in diabetic mellitus. Multiple studies have reported that the activation of PKC leads to increased production of extracellular matrix and cytokines, enhances contractility, permeability and vascular cell proliferation, induces the activation of cytosolic phospholipase A 2 and inhibits the activity of Na + -K + -ATPase. These events are not only frequently observed in diabetes mellitus but are also involved in the actions of vasoactive agents or oxidative stress. Inhibition of PKC by two different kinds of PKC inhibitors -LY333531, a selective PKC-␤-isoform inhibitor, and vitamin E, d-alpha-tocopheron -were able to prevent or reverse the various vascular dysfunctions in vitro and in vivo. Clinical studies using these compounds are now ongoing to evaluate the significance of DAG-PKC pathway activation in the development of vascular complications in diabetic patients.
Introduction
Vascular complications are the major determinants of morbidity and mortality in patients with diabetes mellitus. Recently, the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) have identified hyperglycemia as a major independent risk factor for the manifestation of microvascular and cardiovascular complications in both Type 1 and Type 2 diabetes mellitus. 1, 2 In addition, hyperinsulinemia and insulin resistance have also been recognized as contributing to the risk of the development of hypertension, cardiovascular disease and atherosclerosis in diabetic patients. [3] [4] [5] In the last decade, we and others have shown that activation of the diacylglycerol (DAG)-protein kinase C (PKC) pathway is associated with many vascular abnormalities in the retinal, renal, neural and cardiovascular tissues in diabetes mellitus. [6] [7] [8] [9] [10] [11] [12] In particular, it has been demonstrated that the activation of PKC increases the production of extracellular matrix and cytokines, enhances contractility, permeability and vascular cell proliferation, induces the activation of cytosolic phospholipase A 2 and inhibits Na + -K + -ATPase. 9, 13, 14 These events are not only frequently observed in diabetes mellitus but are also involved in the action of vasoactive agents or oxidative stress. 15 Therefore, PKC may have a pivotal role in the intracellular signal modulation of cardiovascular diseases.
Several studies have suggested the importance of specific PKC isoforms, mainly the ␤and ␦-isoforms, in vascular tissues from diabetic animals. 9, 16 Recently, we have reported the synthesis and characteristics of a specific inhibitor for PKC-␤-isoforms, LY333531, which has shown efficacy in the treatment of diabetic vascular abnormalities. 16 This inhibitor has at least a 10-fold selectivity for PKC-␤ compared with other isoforms. 16 Until now there have been very few isoform-specific compounds, even though the multiplicity of PKC isoforms has been one of the motivating forces of drug development in this area, which may one day offer therapeutic options for many diseases such as cancer, autoimmune disease, inflammation, and diabetic complications.
The following section reviews the molecular, biochemical and physiological findings associated with DAG-PKC pathway activation and the potential options for pharmacological intervention using isoform-specific PKC inhibitors or antioxidant vitamin E in the prevention and/or treatment of cardiovascular dysfunctions in diabetes mellitus.
The family of PKCs includes at least 12 isoforms (␣, ␤I, ␤II, ␥, ␦, ⑀, , , , /, ) (for review see 13, 18, [20] [21] [22] [23] [24] [25] (Table  1) . Each PKC isoform is a separate gene product with the exception of PKC-␤I and ␤II, which are alternatively spliced variants of the same gene product. PKC has been identified as the cellular receptor for the lipid second messenger DAG, and is therefore a key enzyme in the signaling mechanisms by activation of receptors coupled to phospholipase C, which leads to a transient elevation in DAG levels. Furthermore, PKC is a high-affinity receptor for phorbol ester tumor promoters such as 12-O-tetradecanoylphorbol-13-acetate (PMA). 13, 14 Each PKC isoform consists of a single polypeptide chain with two structurally well-defined domains: the amino-terminal regulatory domain and the carboxyl-terminal catalytic domain (Figure 1 ). The former possesses the motifs involved in the binding of the phospholipid cofactors and Ca 2+ and participates in protein-protein interactions that regulate PKC activity and localization, whereas the latter is the kinase domain and includes motifs involved in ATP and substrate binding. All isoforms possess both regions that are highly conserved between different PKC enzymes (regions C1 to C4) and regions that vary considerably (regions V1 to V5) ( Figure 1 ). The C1 region contains a pseudosubstrate sequence, which is an autoinhibitory domain that binds to the substrate binding site on the C4 region in the catalytic domain to keep the enzyme in an inactive state in the absence of cofactors and activators. 26 Notably, the C3 domain possesses the binding site for ATP, the phosphate donor for phosphotransferase activity (see below). PKC isoforms are grouped into three different subclasses according to the regulatory properties conferred by specific domains in the proteins (Table 1, Figure 1 ). Conventional or classical PKCs (␣, ␤, ␤2, ␥), cPKCs, are calcium-dependent and contain two cysteine-rich, zinc-finger-like motifs (C1 region), which are binding sites of DAG or phorbol ester, and a Ca 2+ /phospholipid binding site (C2 region). Novel or new PKCs (␦, ⑀, , , ), nPKCs, are DAG/phorbol ester-sensitive but Ca 2+ -independent probably owing to the absence of the putative C2 region. How-ever, the nPKCs include a C2-like domain close to the amino-terminal end which is unable to bind Ca 2+ . 27 Finally, the atypical PKCs and (its mouse homolog has been named PKC-), aPKCs, are rather insensitive to DAG/phorbol ester because they lack one of the cysteinerich motifs in their C1 region, but can be activated by phosphatidylserine 28 (Table 1) . A related enzyme, PKC-(also called PKD), displays multiple unique features that makes it a distant relative in the PKC family. 29 Recent biochemical and biophysical studies have revealed that PKC activity is regulated not only by different lipid cofactors, 14, 25 but also by phosphorylation events 25 or by specific binding proteins. [23] [24] [25] PKC isoforms are typically activated at the plasma membrane after complexing with diacylglycerol and different membrane phospholipids. 13, 14 The activation is caused by conformational changes that remove the pseudosubstrate sequence from the C4 site on the catalytic domain and, therefore, allow the enzyme to access its protein substrate. 30, 31 The source of DAG that activates PKC can be derived from the hydrolysis of phosphatidylinositides (PI) or from the metabolism of phosphatidylcholine (PC) by phospholipase C (PLC) or D (PLD). Evidence has demonstrated that each isoform could be regulated by more than one lipid second messengers, 30 as in the activation of PKC-by phosphoinositide-3,4,5-triphosphate (PIP 3 ) 14,28,31 ( Figure 2 ). Classically, the activation of calcium-dependent PKC isoforms involves receptor-mediated activation of PLC, resulting in generation of DAG and inositol (1, 4, 5) triphosphate (IP 3 ) from membraneassociated phosphotidyl inositol(4,5)-bisphosphate. Subsequently, IP 3 stimulates the release of intracellular cal- cium, which then binds to the C2 region of the PKC enzyme and promotes its translocation from the cytosol to the plasma membrane. 13 However, cofactor regulation within each PKC subclass is similar, suggesting that additional mechanisms must be active in the differential modulation of the multiplicity of isoform function. An emerging theme in the regulation of PKC function is the prevalence of phosphorylation events. Recent studies have shown that phosphoinositide-dependent protein kinase-1 (PDK-1) may be a universal PKC kinase because PDK-1 can phosphorylate and thereby directly activate cPKCs, nPKCs and aPKCs. 32, 33 This transphosphorylation of the activation loop by PDK-1 is then followed by autophosphorylation on two additional serine/theronine residues within the carboxyl terminus of the PKC sequence. In PKC-␤2, these residues correspond to Thr500 in the activation loop, and Thr641 and Ser660 at the carboxyl terminus, 34, 35 and have been shown to be necessary for the localization of PKC isoforms 36 and to obtain a catalytically competent conformation. [34] [35] [36] Lately, Nishizuka and collaborators have demonstrated that PKC isoforms can also be activated through tyrosine phosphorylation within the regulatory domain in response to H 2 O 2 , suggesting a mechanism unrelated to receptor-coupled hydrolysis of inositol phospholipids. 37 However, the role of tyrosine phosphorylation for PKC activation is still being debated. Beside cofactor regulation and phosphorylation events, binding proteins of PKCs may play an important role in the regulation of PKC. [23] [24] [25] 38 Previous studies suggested that distinct subcellular localization of activated PKC isoforms is mediated by their binding to isoform-spe-cific RACKs (receptors for activated C-kinase). 23 The identification of peptides that interfere with or promote these protein-protein interactions of PKCs with isoformspecific anchoring proteins recently enabled Mochly-Rosen et al to study the specific in vivo roles of various cardiac PKC isoforms. 24 Using cardiomyocyte-specific transgenic expression of these peptide translocation inhibitors or activators, it has been shown that modulation of the interaction of the PKC-⑀-isoform and its membrane anchor, RACK, interferes with physiological cardiomyocyte growth of the normally developing postnatal mouse. 24 This study elegantly confirms the functional importance for intracellular localization of isoform-specific events where PKC binding proteins bind PKC isoforms directly via a non-substrate binding site and may or may not be PKC substrates themselves. 24
Hyperglycemia induces de novo synthesis of DAG and activation of PKC
Many in vivo and in vitro studies have suggested that increased DAG levels in vascular tissues, including the retina, 39 aorta, heart, 40 and renal glomeruli 10, 16, 41 are related to PKC activation in diabetes mellitus. Additionally, among non-vascular tissues, the liver and skeletal muscle, 42, 43 but not the central nervous system or peripheral nerves, 39, 44 display an increased activation of the DAG-PKC pathway in diabetic animals ( Table 2 ). The direct role of hyperglycemia in causing the elevation of DAG levels was established using cultured vascular cells where elevating glucose levels from 5.5 mM to 22 mM increased DAG levels to a maximum after 3-5 days in retinal endothelial cells, 39 aortic endothelial and smooth muscle cells, 40 and renal mesangial cells. 45, 46 Xia et al 47 demonstrated that DAG levels were chronically increased in the aorta of diabetic dogs even after 5 years of disease. In fact, Inoguchi et al have reported that euglycemic control by islet cell transplant for 3 weeks was able to reverse the increases in DAG and PKC levels Table 2 Summary of DAG level and PKC activity in various cultured cells exposed to high glucose and mammalian tissues isolated from diabetic animals.
Diacylglycerol
Protein kinase C in the heart, but not in the aorta of diabetic rats. 40 These results clearly suggested persistently maintained DAG-PKC activation without downregulation in the diabetic state.
The increased levels of DAG can be generated from multiple pathways as described above (Figure 2 ). PKC can be derived from the hydrolysis of PI or from the metabolism of PC by PLC or by PLD, resulting in the production of phosphatidic acid, which is converted to DAG by phosphatidic acid phosphomonoesterase. 13 However, other studies have pointed out that it is unlikely that these pathways are involved in the diabetes-induced elevation of DAG. 40, [47] [48] [49] Alternatively, DAG can be synthesized de novo from glycolytic intermediates. In metabolic labeling studies, 40, 41, 47 we have reported that the incorporation of glucose into the glycerol backbone of DAG was increased in the high glucose condition, suggesting that increased DAG contents were partly derived from a de novo synthesis of DAG from glycerol 3-phosphate. This process requires a stepwise acylation catalyzed by glycerol-3-phosphate acyltransferase and monoacylglycerol-3-phosphate acyltransferase. 50, 51 The first enzyme has specificity for saturated fatty acyl-coenzyme A, whereas the latter is selective for unsaturated fatty acyl-coenzyme A. 52 DAG, which contains both saturated and unsaturated fatty acids, including 1-palmitoyl-2-oleoylsn-glycerol, appears to be active in stimulating PKC, although 1-stearoyl-2-arachidonyl-sn-glycerol may be the most active. 53 Accordingly, DAG generated via this de novo pathway contains palmitoyl-2-oleoyl-sn-glycerol which is capable of activating PKC. It is also possible that DAG could be partly derived from the metabolism of PC owing to the activation of PLD, as another report has suggested. 54 Lastly, the activation of the DAG/PKC pathway induced by hyperglycemia could be the result of glyco-oxidation since there is evidence that oxidants such as H 2 O 2 can activate PKC either directly or by increasing DAG production (see below). 37, 55 
Effect of diabetes mellitus on activating specific PKC isoforms
Among the various PKC isoforms in vascular cells, PKC-␤ and ␦-isoforms appear to be preferentially activated in the aorta, 40,56 kidney 57,58 and heart of diabetic rats 40 and in cultured rat aortic smooth muscle cells 56 exposed to high levels of glucose. This activation has been determined by immunoblot analysis of the membrane fraction which represents the active pool of PKC. In the retina of diabetic rats, PKC-␣, ␤1, ␤2, and ⑀ isoforms were reported to be activated 39 and PKC-␣, ␤ 1 and ␦ were activated in the renal glomeruli. 57, 58 However, in all the vascular tissues, PKC-␤-isoforms exhibit a greater increase in the membrane than the other isoforms. In contrast, activation of PKC-␣-and -isoforms have also been reported in cultured mesangial cells, 59 although the mechanism for activation of PKC-, which is DAG-independent, is unclear.
Possible mechanisms for the predominant isoform-specific activation of PKC-␤ could include cofactor activation, 14, 25 regulation by phosphorylation 25, [32] [33] [34] [35] [36] [37] and/or by targeting proteins 23-25 as described above. Therefore, one of the possible mechanisms for the preferential activation of PKC-␤ in diabetes mellitus is that the ␤-isoforms are more sensitive than the ␣-isoform to DAG, especially at a lower concentration of Ca 2+ . 17 In contrast to the hydrolysis of phosphatidylinositol, which simultaneously produces DAG and inositol 1,4,5-trisphosphate, the de novo synthesis of DAG is not clearly accompanied by elevation of intracellular Ca 2+ . Hence, DAG generated from the de novo pathway, occurring as it does in the absence of a parallel rise in Ca 2+ , may preferentially activate the PKC-␤-over the PKC-␣-isoform. Alternatively, the diabetic state could increase DAG levels at certain subcellular sites such as the mitochondria and the Golgi complex, where metabolism of glucose takes place. This would lead to the preferential activation of PKC-␤-isoforms since they are located intracellularly, whereas PKC-␣ is located close to the plasma membrane in most cells in vascular tissues. 60 Finally, the preferential activation of PKC-␤ potentially could be due to differences in the protein synthesis or degradation of the various PKC isoforms.
Involvement of PKC activation in vascular abnormalities in the diabetic state
In the diabetic state, many vascular alterations at the cellular, histological, and functional levels have been described. Multiple changes, including altered hemodynamics, basement membrane thickening and extracellular matrix change, vascular permeability, cellular growth, angiogenesis and decrease of Na + -K + -ATPase activity have been associated with the activation of PKC.
Altered vascular contractility and blood flow
Abnormal hemodynamic changes such as blood flow and vascular contractility are frequently observed in many tissues of diabetic patients and animals including kidney, retina, skin, arteries, and peripheral nerves, and can be related to PKC activation.
It has been well established that hemodynamic alterations in the kidney, such as increased renal glomerular filtration rate (GFR) and a modest increase of renal blood flow (RBF), precede diabetic nephropathy in patients and experimental diabetic animal models. [61] [62] [63] These changes are likely to be related to decreases in arteriolar resistance, mostly of the afferent arterioles, 64, 65 leading to a chronic elevation of glomerular filtration pressure. This effect of hyperglycemia can be mimicked in vitro by incubating renal mesangial cells with elevated glucose levels, which reduces cellular response to vasoconstrictors. 66 Several mechanisms, including an enhanced activity of angiotensin and increases in the activities of nitric oxide (NO) and of vasodilatory prostanoids such as prostaglandin E 2 (PGE 2 ) or prostaglandin I 2 (PGI 2 ), [67] [68] [69] have been suggested to explain these early alterations of hemodynamics in the diabetic kidney. Interestingly, it is possible that activation of PKC may be involved in all of these mechanisms by enhancing the action or production of these hormones.
Activation of cytosolic phospholipase A 2 (cPLA 2 ), a key enzyme of arachidonic acid production, may be responsible for the increased production of PGE 2 and PGI 2 shown in vivo in glomeruli of diabetic rats and in cultured mesangial cells exposed to high glucose conditions. [70] [71] [72] [73] [74] Activation of Vascular Medicine 2000; 5: [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] cPLA 2 by phosphorylation on serine residues has been determined to occur through PKC-and/or mitogen-activated protein kinase (MAPK)-dependent pathways. 75, 76 Recently, it has been demonstrated that moderate hyperglycemia can also activate the p38 MAP kinase pathway, which has been shown to stimulate cPLA 2 activity, 77 via a PKC-␦-isoform-dependent pathway. 78 Thus, the increased prostaglandin production in glomeruli in diabetes may also be associated with hyperglycemia-induced PKC activation. However, angiotensin can also mediate some of its function through DAG-PKC pathway activation. 67, 68, 79 Further, changes in the bioactivity of nitric oxide (NO) are known to be associated with abnormalities of blood flow and contractility leading to glomerular hyperfiltration in the diabetic state. 80, 81 These studies suggest that renal NO production may be increased in diabetes mellitus via PKCinduced inducible nitric oxide synthase (iNOS) overexpression. In contrast, it has been reported that NO production and cyclic guanosine monophosphate (cGMP) generation in response to cholinergic stimuli are decreased in glomeruli isolated from diabetic rats and that PKC inhibitors restore the normal glomerular cGMP response. [82] [83] [84] Another study has reported a decrease in the expression of neural NOS (nNOS) mRNA in the juxtaglomerular macula densa cells of diabetic rats, 85 which could induce glomerular hyperfiltration by inhibiting renin secretion. 86, 87 Thus, PKC can regulate renal hemodynamics by increasing or decreasing NO production depending on the cell type, tissue location and duration of diabetes.
Many studies have supported the view that PKC activation is involved in decreasing retinal blood flow in various animal models with a short duration of diabetes mellitus. [88] [89] [90] [91] [92] Recently, PKC activation has also been shown to play a part in the development of diabetic neuropathy owing to an increase in vascular resistance at the microcirculatory level. 93, 94 On the other hand, retinal blood flow appears to be unchanged or increased with a longer duration of diabetes or evidence of clinical retinopathy. 95 Nevertheless, it has been shown that decreased retinal blood flow can be mimicked by intravitreous injection of phorbol ester. 39 In addition, retinal blood flow abnormalities found in diabetic rats were normalized by intravitreous introduction of PKC inhibitors, 16 suggesting that activation of PKC can have a functional role in retinal blood flow, possibly through vasoconstrictive processes. 96 Although an exact mechanism explaining how PKC activation can cause retinal vasoconstriction has not yet been identified, both impaired NO-mediated vasodilation and an increase of endothelin-1 (ET-1) expression in the retina have been proposed. Recently, it has been reported that the PKC upregulation on exposure to high ambient glucose concentrations impairs NO-mediated vasodilation in diabetes by inhibiting endothelial nitric oxide synthase (eNOS) expression in cultured retinal microvascular endothelial cells. 97 Furthermore, calcium flux and PKC activation induced by high glucose levels may inhibit the expression of iNOS in vascular smooth muscle cells. 98 Alternatively, we have reported that the expression of endothelin-1 (ET-1), a potent vasoconstrictor, is increased in the retina of diabetic rats. Correspondingly, an antagonist to ET-1's receptor (ETA) is able to prevent the decrease in retinal blood flow in diabetic rats. 99 These findings using PKC inhibitors and ET-1 antag-onist are consistent because ET-1 mediates many of its effects by the activation of PKC. 100 In large vessels of diabetic patients, the relaxation phase in peripheral arteries after acetylcholine stimulation appears to be delayed or blunted. [101] [102] [103] The impaired vascular relaxation can be restored by PKC inhibitors and mimicked by phorbol ester, 104 suggesting that PKC activation has an important role in causing abnormal peripheral hemodynamics in diabetes. In the microcirculation of diabetic patients, several clinical studies from Tooke et al have demonstrated early hemodynamic changes exhibiting increased microvascular pressure, flow and permeability. 105 These studies suggested that hemodynamic injury to the microvascular endothelium can lead to adaptive microvascular sclerosis, contributing to a loss of vasodilatory reserve and autoregulatory capacity with increasing disease duration. 105 Consistent with the role of PKC in the suppression of vascular relaxation in diabetes mellitus, PKC activation in aortic endothelial cells can reduce mRNA expression of cNOS 106 and NO's enzymatic activity. 107 Furthermore, PKC can also regulate vascular contractility in diabetes mellitus through altered expression of contractile proteins like caldesmon, 108 resulting in increased contraction and decreased vascular blood flow.
Basement membrane thickening and extracellular matrix change
Thickening of capillary basement membranes and matrix expansion are the most prominent structural abnormalities of the vasculature or mesangium encountered in early diabetes mellitus. 109 The functions of the basement membrane are complex and varied: it can be involved in vascular permeability, cellular adhesion, proliferation, differentiation, and gene expression. 110 Multiple studies have pointed out that the diabetic state induces changes in the basement membrane, including increases in type IV and VI collagen, and in fibronectin, as well as decreases in proteoglycans. [111] [112] [113] [114] [115] [116] These effects have been shown to be prevented by general PKC inhibitors such as staurosporine or calphostin C. [117] [118] [119] [120] Additionally, treatment with PKC agonists stimulated type IV collagen expression 121 and fibronectin accumulation in vitro, 46 indicating the importance of PKC activation in the histological and structural changes of vasculature and mesangium in diabetes mellitus.
Many studies have implicated an increased expression of transforming growth factor ␤ 1 (TGF-␤ 1 ) in the development of mesangial expansion and basement membrane thickening in diabetes mellitus. 30 TGF-␤ 1 , a prototypical multifunctional cytokine, stimulates the production of matrix components such as type IV collagen, fibronectin, and laminin in cultured mesangial cells 122, 123 and glomerular epithelial cells. 124 Several in vivo studies have reported increased TGF-␤ 1 expression in the kidney of diabetic animals and diabetic patients. [125] [126] [127] [128] [129] [130] Inhibition of TGF-␤ 1 activity by a specific neutralizing antibody significantly reduced collagen synthesis and gene expression of type IV collagen and fibronectin in the renal cortex 131 and glomeruli from diabetic rats 132 and in cultured mesangial cells exposed to high glucose levels. 133 It is well known that PKC activation induces the synthesis of type IV collagen and fibronectin. 34, 134 It has also been shown that PKC activation is a key intermediary in the process by which TGF-␤ 1 and angiotensin II cause DNA synthesis and mesangial Vascular Medicine 2000; 5: [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] cell matrix protein production. 135 Furthermore, PKC inhibitors have been shown to decrease TGF-␤ 1 expression by high glucose and may prevent the mesangial expansion observed in diabetic nephropathy. 10, 30, 57 One possible mechanism by which high glucose increases the expression and synthesis of TGF-␤ 1 and extracellular matrix is by PKC's actions on inducing the transcription factors c-fos and c-jun. Increased mRNA expression of c-fos and c-jun proto-oncogenes has been demonstrated in cultured mesangial cells treated with high glucose levels 136 and in rat glomeruli 24 h after induction of diabetes. 137 Activation of PKC is known to induce transcription of c-fos and c-jun, 138, 139 which are proto-oncogenes regulating gene transcription through the AP-1 binding site. 134, 140 Promoter regions of TGF-␤ 1 , 141 fibronectin 142 and laminin 143 contain the AP-1 binding consensus sequences, supporting the view that PKC activation by hyperglycemia could be responsible for the increased levels of matrix protein synthesis either directly or through overexpression of TGF-␤ 1 .
Vascular permeability, cell growth, and angiogenesis
PKC activation is also involved in increased vascular permeability, cell growth, and neovascularization of the endothelium, all well-known diabetic vascular abnormalities. PKC activation can directly increase the permeability of albumin and other macromolecules, [144] [145] [146] [147] possibly by phosphorylating cytoskeletal proteins forming the tight junctions [148] [149] [150] [151] [152] or by regulating the expression or activity of various growth factors. [153] [154] [155] [156] [157] For example, PKC␤-I overexpression in human dermal microvascular endothelial cells has been reported to enhance phorbol ester-induced increases in permeability to albumin, 158 which is consistent with the preferential activation of PKC-␤-isoforms in diabetes. Recently, it has been shown that high glucose concentration increases endothelial cell permeability via activation of PKC-␣. 159 Furthermore, PKC inhibitors are known to attenuate glucose-induced elevation in albumin permeability, indicating a crucial role for PKC activation in regulating endothelial barrier function. 147 Thus, the actions of hyperglycemia in endothelial barrier function can be at least partly mediated through activation of specific PKC isoforms.
PKC activation can also regulate vascular permeability and neovascularization via the expression or regulation of various growth factors. [153] [154] [155] [156] [157] Recent studies have implicated several growth factors in the pathogenesis of proliferative diabetic retinopathy. [155] [156] [157] Vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) have been reported to be implicated in the neovascularization process of proliferative diabetic retinopathy. 157 We have reported that VEGF mediates its mitogenic and permeability-inducing actions in endothelial cells by activating the PKC-␤-isoform through tyrosine phosphorylation of phospholipase C␥. 160 Inhibition by PKC-␤ selective inhibitor LY333531 in vitro and in vivo prevents VEGF-induced endothelial proliferation, angiogenesis, and permeability. 16, 161 In addition, Williams et al have shown that the expression of VEGF was increased in human aortic smooth muscle cells by elevating the glucose concentration and was inhibited by PKC inhibitors. 162 Clinical studies by our laboratory and others have provided strong data correlating VEGF levels in the retina with pre-existing neovascu-larization in diabetic patients. 157 These results have provided intriguing evidence that PKC activation induced by hyperglycemia could alter the expression and action of growth factors and cytokines that mediate vascular dysfunction locally, as observed in the retina. Na + -K + -ATPase activity change Na + -K + -adenosine triphosphatase (Na + -K + -ATPase), a component of the sodium pump involved in cellular contractility, growth, and differentiation, 163 has been shown to be decreased in vascular and neuronal tissues of diabetic patients and animal models. 7, [164] [165] [166] We reported that the inhibition of Na + -K + -ATPase by hyperglycemia was due to activation of PKC and a subsequent increase in cPLA 2 activity. 167 This stimulation increases the production of arachidonic acid and prostaglandin E 2 (PGE 2 ) levels, which have been reported to inhibit Na + -K + -ATPase. [168] [169] [170] [171] It has also been demonstrated that specific inhibitors of PKC and cPLA 2 will prevent the inhibition of Na + -K + -ATPase induced by high glucose. 167
PKC inhibitors and their effects in cardiovascular disease
Although a wealth of inhibitory compounds for PKC action are available, only a few demonstrate specificity for PKC alone or for individual PKC isoforms. 16, 23, 172, 173 According to their site of interaction within the PKC protein structure, regulatory domain inhibitors may target the phospholipid or phorbol ester binding site, whereas catalytic domain inhibitors are directed to either the substrate site or ATPbinding site (see above). The majority of the compounds that are most promising as selective PKC inhibitors are targeted to the ATP-binding site of the catalytic domain and belong either to the indolocarbazole or bisindoylmaleimide class of compounds. The bisindoylmaleimide, LY333531, which specifically inhibits PKC-␤, is the most selective and clinically promising agent developed to date. 16, 57, 161, 174 However, other approaches to inhibit PKC activity such as vitamin E (d-␣-tocopherol), 175 antisense oligonucleotides 23, 176 or peptide fragment inhibitors and activators of PKC translocation 177, 178 have demonstrated potential benefits in cardiovascular diseases. Here we will focus on studies involving the novel selective PKC-␤ inhibitor, which could represent an important therapeutic agent to be used for various disease states, including cardiovascular disease and cancer.
The specificity of the PKC-␤ inhibitor LY333531 was evaluated by an in vitro study examining the PKC isoforminduced phosphorylation of myelin basic protein. 174 LY333531 inhibited PKC-␤I and ␤II with a half-maximal inhibitory constant (IC 50 ) of 4.5 nM and 5.9 nM, respectively, whereas the IC 50 was 250 nM or greater for other isoforms. 174 The kinetic analysis showed that LY333531 was a competitive inhibitor for ATP, with a K i of 2 nM for PKC-II␤. 174 LY333531 is several orders of magnitude more selective for inhibition of PKC-␤ compared with other ATP-dependent kinases such as calcium calmodulin or src tyrosine kinase, compared with which it is 1060-fold more selective and 2200-fold more selective, respectively. 174 A substantial amount of information has been generated Vascular Medicine 2000; 5: [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] regarding the role of the PKC-␤-isoforms in diabetic vascular disease using LY333531. We have reported that abnormal retinal and renal hemodynamics and the increases in albuminuria in streptozotocin-induced diabetic rats can be ameliorated using an orally administered dosage (0.1-10 mg/kg) of LY333531, in parallel with the inhibition of diabetes-induced PKC activation in the retina and renal glomeruli. 16 No toxicity of the compound was observed. In rat retinal tissue, diabetes-induced reductions in Na + -K + -ATPase and calcium ATPase activities were normalized by LY333531 treatment. 179 In addition, PKC-␤ inhibition also effectively inhibited preretinal and optic nerve head neovascularization in the pig model of branch retinal vein occlusion. 180 Furthermore, its specificity was confirmed while demonstrating that the PKC-␤-specific inhibitor LY333531 prevented the increase in phosphorylation of PKC-␤I but not the ␣-isoform in isolated glomeruli from control and streptozotocin-induced diabetic rats. 56 In addition, LY333531 also prevented the diabetes-induced abnormalities in mRNA expression of TGF-␤ 1 , type IV collagen, and fibronectin in glomeruli. 56 Recently, Koya et al provided the first in vivo evidence that the long-term inhibition of PKC activation by this PKC-␤ inhibitor can ameliorate glomerular pathologies in diabetic db/db mice. 181 LY333531 (50 mg/kg) was also reported to prevent decreased motor nerve conduction velocity and sciatic nerve blood flow in the diabetic rat. 93 In addition, inhibition of PKC-␤ activity using LY333531 has been shown to be beneficial in cardiac dysfunction. [182] [183] [184] Administration of LY333531 improved depressed cardiomyocyte function by increasing myofilament responsiveness to calcium in hearts obtained from transgenic mice overexpressing PKC-␤. 183 In addition, LY333531 significantly decreased elevated PKC activity in membrane fractions of failed human hearts, suggesting selective inhibition of the PKC-␤-isoform to be an suitable therapeutic strategy for the prevention and treatment of heart failure. 184 Since a few reports have shown that glucose-dependent PKC activation and translocation can be observed in patients with non-insulin-dependent diabetes mellitus, [185] [186] [187] these findings provide strong evidence that the activation of PKC isoforms is involved in the development of diabetic vascular complications. Clinical trials are now ongoing to evaluate the efficacy of LY333531 on pathological changes in cardiovascular disease diabetic retinopathy, neuropathy and peripheral vascular disease.
Antioxidant treatment (vitamin E, d-␣tocopherol) and its effect in cardiovascular disease
Increased oxidative stress induced by hyperglycemia has been implicated in the aforementioned effects in the vascular tissues of diabetic patients and animals. 188, 189 Previous studies have reported that antioxidants such as vitamin E (d-␣-tocopherol) can inhibit DAG-PKC pathway activation in cultured vascular smooth muscle cells by growth factors or rat vascular tissues after exposure to growth factor or high glucose levels. 56, 190, 191 We have shown that high levels of vitamin E, possibly independently of its antioxidant effects, can inhibit PKC activation by decreasing DAG levels, 56, 190 not by directly altering PKC because the direct addition of vitamin E to purified PKC-␣-or ␤-isoforms in vitro did not have any inhibitory effect. 190 Recently, the activation of DAG kinase induced by high levels of vitamin E has been postulated as a preceding step in the inhibition of PKC because DAG kinase metabolizes DAG to phosphatidic acid and subsequently decreases PKC activity. 192 Based on the results of a small clinical trial, we have reported that vitamin E treatment can normalize retinal blood flow and renal function in patients with Ͻ10 years of Type 1 diabetes without inducing a significant change in glycemic control. 193 Patients were randomly assigned to either a high-dose treatment with 1800 IU vitamin E/day or placebo for 4 months and followed, after treatment crossover, for a further 4 months. These results confirm earlier physiological studies in animals which have shown that prevention of the abnormal hemodynamics in the retina and kidney and increased albuminuria occurred in parallel with the inhibition of DAG-PKC activation. 190, 192 However, in the HOPE (Heart Outcomes Prevention Evaluation) study, vitamin E supplementation (400 IU/day) did not lower the risk for cardiovascular outcome significantly. 194 This study represented a large, simple, randomized trial of two widely applicable treatments of either an angiotensin-converting enzyme inhibitor (ranipril) or vitamin E to prevent myocardial infarction, stroke or cardiovascular death in a high-risk population. The HOPE study included a total of 2545 women and 6996 men aged 55 years or older who were at high risk for cardiovascular events because they had cardiovascular disease or diabetes in addition to one other risk factor. It is speculated that a likely reason for the lack of significant effect in the vitamin E treatment group was the low dose of vitamin E (400 IU/day) administered, which at a comparable regimen was unable to inhibit PKC activities in the vascular tissue of diabetic animals. 
Summary and perspectives
Thus, many studies have demonstrated that high glucose levels or other metabolic changes, such as elevation of fatty acid and oxidative stress, in diabetes can activate the DAG-PKC pathway in vascular tissue. The activation of the DAG-PKC pathway is associated with many vascular abnormalities in the retinal, renal, neural and cardiovascular tissues (Figure 3 ) observed in this condition. These findings clearly indicate the importance of the activation of the DAG-PKC pathway as a common cellular downstream mechanism in many microcardiovascular diseases, particularly in diabetes mellitus. Among the various PKC isoforms, the ␤and ␦-isoforms appear to be activated preferentially by diabetes. Clinical studies are now in progress to determine whether isoform-specific inhibitors to the PKC-␤-isoform, LY333531 can prevent various diabetic complications or improve the outcomes for patients with cardiovascular disease.
